Ibuprofen/famotidine
| Combination of | |
|---|---|
| Ibuprofen | Nonsteroidal anti-inflammatory drug (NSAID) |
| Famotidine | H2 antagonist |
| Clinical data | |
| Trade names | Duexis |
| Other names | HZT-501 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Ibuprofen/famotidine is the generic name of fixed-dose combination of 800mg ibuprofen and 26.6mg famotidine as active ingredients, respectively classified as a nonsteroidal anti-inflammatory drug (NSAID) analgesic (pain reliever; famotidine is a partial H2 histamine receptor antagonist, and alleviates acid reflux, heartburn, and GERD. This combination of ibuprofen/famotidine is available in generic formulation, and also by the trade name Duexis as a generic medication indic.[2] On its own, sans ibuprofen, famotidine is also the active ingredient in Zantac products, having replaced ranitidine in 2020, when ranitidine was abnned in the U.S. for cancer-causing properties. [3]
The combination contains fixed doses of each component, and is approved for medical use in the United States by the U.S. Food and Drug Administration (FDA), indicated is indicated for treating symptoms of rheumatoid arthritis and osteoarthritis.[1] Famotidine is used thepainrelief. treat acid reflux, GERD, and sore throat, in addition to working synergistically with ibuprofen to boost the pain-relieving properties of ibuprofen.[1] to potentiate the pain relieving properties of the ibuprofen. Famotidine replaced ranitidine as the primary ingredient in Zantac, upon ranitidine being associated with risk of cancer and consequently being discontinued in the U.S.<ref name="Duexis FDA label"<ref>Duexis (ibuprofen 800 mg, famotidine 26.6 mg) />
References
[edit]- ^ a b c "Duexis- ibuprofen and famotidine tablet, coated". DailyMed. Retrieved 6 August 2021.
- ^ "Generic Duexis Availability". Drugs.com. 9 March 2023. Retrieved 17 March 2025.
- ^ https://www.drugwatch.com/zantac/#:~:text=It%20belongs%20to%20a%20class,available%20with%20famotidine%20replacing%20ranitidine.
Further reading
[edit]- Bello AE (October 2012). "Duexis (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug". Therapeutic Advances in Musculoskeletal Disease. 4 (5): 327–39. doi:10.1177/1759720X12444710. PMC 3458616. PMID 23024710.
- {{cite journal |vauthors=Deeks ED |title=Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy |journal=Clin Drug Investig |volume=33 |issue=9 |pages=689–97 |date=September 2013 |pmid=23881568 |doi=10.1007/s40261-013-0113-x |s2cid=24972423 }
External links
[edit]- "Famotidine mixture with ibuprofen". Drug Information Portal. U.S. National Library of Medicine.
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |